Ana F. Best

Ana F. Best

Auto-generated profile, based on publicly available information

Ana F. Best

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2016 in Cancer
Verified
Journal Article
Open access
PDF file
PMPhuong L. Mai
Phuong L. Mai
ABAna F. Best
Ana F. Best
JPJune A. Peters
June A. Peters
RDRosamma M. DeCastro
Rosamma M. DeCastro
PKPayal P. Khincha
Payal P. Khincha
SSSharon A Savage
Sharon A Savage
BACKGROUND: Li‐Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome characterized by a very high lifetime cancer risk and an early age at diagnosis of a wide cancer spectrum. Precise estimates for the risk of first and subsequent cancers are lacking.METHODS: The National Cancer Institute's Li‐Fraumeni Syndrome Study includes families meeting the diagnostic criteria for LFS or Li‐Fraumeni‐like syndrome, and individuals with a germline TP53 mutation, choroid plexus carcinoma, adrenocortical carcinoma, or ≥3 cancers. Herein, we estimated the cumulative risk and annual hazards for first and second cancers among TP53 mutation carriers (TP53 positive [TP53+]) using MATLAB statistical software.RESULTS: This study evaluated 286 TP53+ individuals from 107 families. The cumulative cancer incidence was 50% by age 31 years among TP53+ females and 46 years among males, and nearly 100% by age 70 years for both sexes. Cancer risk was highest after age 20 years for females, mostly due to breast cancer, whereas among males the risk was higher in childhood and later adulthood. Among females, the cumulative incidence rates by age 70 years for breast cancer, soft tissue sarcoma, brain cancer, and osteosarcoma were 54%, 15%, 6%, and 5%, respectively. Among males, the incidence rates were 22%, 19%, and 11%, respectively, for soft tissue sarcoma, brain cancer, and osteosarcoma. Approximately 49% of those with 1 cancer developed at least another cancer after a median of 10 years. The average age‐specific risk of developing a second cancer was comparable to that of developing a first cancer.CONCLUSIONS: The cumulative cancer risk in TP53 + individuals was very high and varied by sex, age, and cancer type. Additional work, including prospective risk estimates, is needed to better inform personalized risk management. Cancer 2016;122:3673‐81. © 2016 American Cancer Society.

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
MSMeredith S Shiels
Meredith S Shiels
PCPavel Chernyavskiy
Pavel Chernyavskiy
WAWilliam F Anderson
William F Anderson
ABAna F Best
Ana F Best
EHEmily A Haozous
Emily A Haozous
AGAmy Berrington de Gonzalez
Amy Berrington de Gonzalez

20 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
STSara M. Tolaney
Sara M. Tolaney
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
JWJulia White
Julia White
VBVictoria S. Blinder
Victoria S. Blinder
JFJared C. Foster
Jared C. Foster
LKLarissa A. Korde
Larissa A. Korde
PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvements in outcomes, a panel of experts reviewed the STEEP criteria to determine whether modifications are needed.METHODS: We conducted systematic searches of ClinicalTrials.gov for adjuvant systemic and local-regional therapy trials for breast cancer to investigate if the primary end points reported met STEEP criteria. On the basis of common STEEP deviations, we performed a series of simulations to evaluate the effect of excluding non–breast cancer deaths and new nonbreast primary cancers from the invasive disease–free survival end point.RESULTS: Among 11 phase III breast cancer trials with primary efficacy end points, three had primary end points that followed STEEP criteria, four used STEEP definitions but not the corresponding end point names, and four used end points that were not included in the original STEEP manuscript. Simulation modeling demonstrated that inclusion of second nonbreast primary cancer can increase the probability of incorrect inferences, can decrease power to detect clinically relevant efficacy effects, and may mask differences in recurrence rates, especially when recurrence rates are low.CONCLUSION: We recommend an additional end point, invasive breast cancer–free survival, which includes all invasive disease–free survival events except second nonbreast primary cancers. This end point should be considered for trials in which the toxicities of agents are well-known and where the risk of second primary cancer is small. Additionally, we provide end point recommendations for local therapy trials, low-risk populations, noninferiority trials, and trials incorporating patient-reported outcomes.

20 June 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JTJoseph E. Tota
Joseph E. Tota
ABAna F. Best
Ana F. Best
ZZZachary S. Zumsteg
Zachary S. Zumsteg
MGMaura L. Gillison
Maura L. Gillison
PRPhilip S. Rosenberg
Philip S. Rosenberg
ACAnil K. Chaturvedi
Anil K. Chaturvedi
PURPOSE: Human papillomavirus–positive oropharynx cancer incidence has increased rapidly in cohorts of US white men born during the 1930s to 1950s. It is unknown how the trajectory of the oropharynx cancer epidemic may be changing in the United States. METHODS: Using US cancer registry information, we investigated whether increases in oropharynx cancer have continued into recent birth cohorts and forecasted the future burden across age, sex, and race/ethnicity subgroups. Log-linear Joinpoint regression and age-period-cohort models were used to evaluate incidence trends during 1992 to 2015 and projections through 2029. RESULTS: Among white men, oropharynx cancer incidence increased rapidly in individuals born during 1939 to 1955 (5.3% per 2-year birth cohort; 95% CI, 4.8% to 5.7%), but this rate of increase significantly moderated in individuals born during 1955 to 1969 (1.7% per 2-year birth cohort; 95% CI, 1.0% to 2.4%). Should these birth-cohort trends continue, from 2016 to 2029 we forecast that incidence will increase dramatically in older white men 65 to 74 years of age (from 40.7 to 71.2 per 100,000) and 75 to 84 years of age (from 25.7 to 50.1 per 100,000), moderately in white men 55 to 64 years of age (from 40.3 to 52.0 per 100,000), and remain stable in white men 45 to 54 years of age (approximately 18 per 100,000). Accounting for population growth, we project an increase in annual number of cases in the United States from 20,124 (95% CI, 19,779 to 20,469) in 2016 to 30,629 (95% CI, 29,413 to 31,845) in 2029, primarily driven by older individuals (age ≥ 65 years; from 7,976 [95% CI, 7,782 to 8,172] to 18,072 [95% CI, 17,271 to 18,895]) and white men (from 14,453 [95% CI, 14,142 to 14,764] to 22,241 [95% CI, 21,119 to 23,364]). CONCLUSION: The exponential increase in oropharynx cancer incidence in young white US men has ebbed, and modest increases are occurring/anticipated in cohorts born after 1955. Continued strong increases in incidence in cohorts born before 1955, and an approximate 50% increase in size of the US population age 65 years or older through 2029, portend a substantial shift in burden to elderly white men.

1 September 2019 in Blood Reviews
Verified
Journal Article
Closed access
MFMoisés O. Fiesco-Roa
Moisés O. Fiesco-Roa
NGNeelam Giri
Neelam Giri
LMLisa J. McReynolds
Lisa J. McReynolds
ABAna F. Best
Ana F. Best
BABlanche P. Alter
Blanche P. Alter

1 December 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MBMandy L. Ballinger
Mandy L. Ballinger
ABAna Best
Ana Best
PMPhuong L. Mai
Phuong L. Mai
PKPayal P. Khincha
Payal P. Khincha
JLJennifer T. Loud
Jennifer T. Loud
SSSharon A Savage
Sharon A Savage
Li-Fraumeni syndrome (LFS) was first described in 1969 as a highly penetrant cancer-prone syndrome.1 Formal diagnostic criteria for LFS have subsequently been developed, based on a family or a personal history of a broad spectrum of early-onset cancers, including sarcoma, breast cancer, adrenocortical carcinoma, and brain tumors, often with more than 1 cancer per affected individual.2-5 Quiz Ref ID Lifetime cancer risks are reported to approach 100% for both sexes in cases identified by family history.6-8 The exceedingly high cancer risk in LFS often confers a high psychological and medical burden.9 Pathogenic variants in the tumor suppressor gene, TP53 (NCBI Entrez Gene 7157), were first identified and subsequently found to cause about 70% of classic LFS in 1990.10-13 Identification of germline TP53 mutation carriers has been augmented by increased with increased sequencing of germline and somatic DNA using gene panels and whole-exome and whole-genome testing, owing in part to the influence of precision medicine initiatives.